Catalio Capital Management LP Trims Stake in GRAIL, Inc. $GRAL

Catalio Capital Management LP reduced its position in shares of GRAIL, Inc. (NASDAQ:GRAL) by 78.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,313 shares of the company’s stock after selling 107,615 shares during the period. Catalio Capital Management LP’s holdings in GRAIL were worth $2,594,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the company. Perigon Wealth Management LLC grew its position in shares of GRAIL by 0.7% during the 4th quarter. Perigon Wealth Management LLC now owns 19,450 shares of the company’s stock valued at $1,665,000 after purchasing an additional 133 shares in the last quarter. Parallel Advisors LLC lifted its holdings in shares of GRAIL by 5.2% during the 4th quarter. Parallel Advisors LLC now owns 2,667 shares of the company’s stock worth $228,000 after acquiring an additional 133 shares during the last quarter. Westmount Partners LLC lifted its holdings in shares of GRAIL by 1.8% during the 4th quarter. Westmount Partners LLC now owns 8,279 shares of the company’s stock worth $709,000 after acquiring an additional 150 shares during the last quarter. Comerica Bank lifted its holdings in shares of GRAIL by 59.2% during the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock worth $27,000 after acquiring an additional 173 shares during the last quarter. Finally, Whittier Trust Co. lifted its holdings in shares of GRAIL by 19.3% during the 4th quarter. Whittier Trust Co. now owns 1,114 shares of the company’s stock worth $95,000 after acquiring an additional 180 shares during the last quarter.

Analyst Ratings Changes

A number of analysts have recently issued reports on GRAL shares. Robert W. Baird set a $70.00 price objective on shares of GRAIL in a report on Wednesday, May 6th. Canaccord Genuity Group dropped their price objective on shares of GRAIL from $105.00 to $80.00 and set a “buy” rating for the company in a report on Friday, February 20th. Wall Street Zen raised shares of GRAIL from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Piper Sandler lifted their price objective on shares of GRAIL from $54.00 to $56.00 and gave the stock a “neutral” rating in a report on Wednesday, May 6th. Finally, The Goldman Sachs Group started coverage on shares of GRAIL in a report on Friday, June 5th. They set a “neutral” rating and a $60.00 price objective for the company. Four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $67.00.

GRAIL News Roundup

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: The stock is getting active trading interest as multiple law firms publicized the August 4, 2026 lead-plaintiff deadline, keeping GRAIL in the spotlight and drawing attention from investors following the sharp prior selloff. Article Title
• Neutral Sentiment: Several firms, including Levi & Korsinsky, Bernstein Liebhard, Rosen, Schall, Pomerantz, Faruqi & Faruqi, Glancy Prongay, and others, reiterated that a securities class action has been filed and that investors who bought shares during the May 13, 2025 to February 19, 2026 period may seek lead-plaintiff status. Article Title
• Negative Sentiment: The underlying allegation remains that GRAIL allegedly withheld detailed NHS-Galleri trial data and misled investors, which could raise legal risk, pressuring sentiment even though no operational update was reported. Article Title

GRAIL Stock Up 2.0%

GRAIL stock opened at $59.45 on Thursday. The company has a market capitalization of $2.55 billion, a PE ratio of -5.73 and a beta of 3.15. The firm has a fifty day simple moving average of $58.55 and a two-hundred day simple moving average of $73.24. GRAIL, Inc. has a twelve month low of $29.95 and a twelve month high of $118.84.

GRAIL (NASDAQ:GRAL) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($2.29) earnings per share for the quarter, topping the consensus estimate of ($2.76) by $0.47. The business had revenue of $40.79 million during the quarter, compared to the consensus estimate of $39.16 million. GRAIL had a negative net margin of 253.22% and a negative return on equity of 16.42%. As a group, equities analysts expect that GRAIL, Inc. will post -10.99 earnings per share for the current fiscal year.

Insider Buying and Selling at GRAIL

In other news, CFO Aaron Freidin sold 45,806 shares of the company’s stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total transaction of $2,286,635.52. Following the completion of the transaction, the chief financial officer directly owned 260,669 shares of the company’s stock, valued at approximately $13,012,596.48. This represents a 14.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Robert P. Ragusa sold 123,502 shares of the company’s stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total transaction of $6,165,219.84. Following the transaction, the chief executive officer directly owned 518,582 shares of the company’s stock, valued at approximately $25,887,613.44. This trade represents a 19.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 232,464 shares of company stock valued at $11,621,242. Company insiders own 1.83% of the company’s stock.

GRAIL Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.